Table 2.
Prevalence of HBV variants carrying amino acid substitutions in HBsAg in positions associated with immune escape.
| Study Region | Year of Sample Collection and Number of HBV Sequences, n | HBV Genotypes/ Serotypes, n (%) |
aa Substitutions in HBsAg Associated with Immune Escape | |||||
|---|---|---|---|---|---|---|---|---|
| aa Substitution * | Number of Sequences Carrying aa Substitution | The Proportion of Sequences with aa Substitution | ||||||
| Per HBV Genotype ** | Total per Region ** | Total per HBV Genotype, Excluding aa Substitutions in Position 118 ** | Total per Region, Excluding aa Substitutions in Position 118 ** | |||||
| Moscow Region | 2008–2010, n = 55 |
A/ad, n = 3 (5.5%) | n.d. | 0 | 0/3 | 0/3 | ||
| D/ay, n = 52 (94.5%) | T118A/V/M | 6/5/1 | 18/52 (34.6%) | 18/55 (32.7%) | 6/52 (11.5%) |
6/55 (10.1%) |
||
| P120Q | 1 | |||||||
| T131I/P | 3/1 | |||||||
| D144E | 1 | |||||||
| 2020, n = 136 |
A/ad, n = 11 (8.1%) | G130N | 1 | 1/11 | 1/11 | |||
| D/ay, n = 125 (91.9%) |
T118A/V | 21/11 | 44/125 (35.2%) | 45/136 (33.1%) | 12/125 (9.6%) |
13/136 (9.6%) |
||
| P120Q | 1 | |||||||
| Q129H/L/P | 1/2 | |||||||
| G130R/S | 1/1 | |||||||
| T131I/N | 1/1 | |||||||
| M133T/I | 3 | |||||||
| G145R | 1 | |||||||
| Tuva Republic | 2008, n = 76 |
A/ad, n = 2 (2.6%) | M133T | 1 | 1/2 | 1/2 | ||
| D/ay, n = 74 (97.4%) | T118A | 13 | 19/74 (25.7%) | 20/76 (26.3%) ▪ | 6/74 (8.1%) |
7/76 (9.2%) |
||
| P120T | 1 | |||||||
| T131N | 1 | |||||||
| M133L/K/I | 1/2 | |||||||
| G145S | 1 | |||||||
| 2021, n = 49 |
A/ad, n = 2 (4.1%) | n.d. | 0 | 0/2 | 0/2 | |||
| D/ay, n = 47 (95.9%) | T118A | 19 | 22/47 (46.8%) | 22/49 (44.9%)▪ | 3/47 (6.4%) |
3/49 (6.1%) |
||
| P120S | 3 | |||||||
| Sakha Republic (Yakutia) | 1997–2009, n = 58 |
A/ad, n = 33 (56.9%) | T126S | 2 | 4/33 (12.1%) | 4/33 (12.1%) |
||
| M133T | 2 | |||||||
| C/ad, n = 2 (3.4%) | n.d. | 0 | 0/2 | 0/2 | ||||
| D/ay, n = 23 (39.7%) | T118A | 2 | 7/23 (30.4%) | 11/58 (19.0%) | 5/23 (21.7%) |
9/58 (15.5%) |
||
| T118A+P120I | 1 | |||||||
| P120S/T | 2 | |||||||
| M133T | 1 | |||||||
| K141Q | 1 | |||||||
| 2018–2022, n = 231 |
A/ad, n = 94 (40.7%) | P120T | 1 | 7/94 (7.4%) ▪▪ | 36/231 (15.6%) | 7/94 (7.4%) |
14/231 (6.1%) |
|
| Q129R | 1 | |||||||
| Q129P | 1 | |||||||
| G130N | 1 | |||||||
| M133T | 2 | |||||||
| C/ad, n = 21 (9.1%) | M133I | 1 | 1/21 (4.8%) | 1/21 (4.8%) | ||||
| D/ay, n = 116 (50.2%) |
T118A/V | 19/4 | 29/116 (25.0%) ▪▪ | 6/116 (5.2%) |
||||
| T118A+Q130R | 1 | |||||||
| T118M+ P120S | 1 | |||||||
| P120S | 1 | |||||||
| G130N+T131H | 1 | |||||||
| T131I/P | 1/1 | |||||||
| Khabarovsk Region | 2008, n = 16 | D/ay, n = 16 (100%) | T118A/V | 1/2 | 4/16 (25%) | 4/16 (25%) | 0/16 (0%) | 0/16 (0%) |
| 2021, n = 65 | A/ad, n = 7 (10.8%) | n.d. | 0 | 0/7 | 0/7 | |||
| C/ad, n = 2 (3.1%) | n.d. | 0 | 0/2 | 0/2 | ||||
| D/ay, n = 56 (86.1%) | T118A/V | 7/2 | 18/56 (32.1%) | 18/65 (27.7%) | 9/56 (16.1%) |
9/65 (13.8%) |
||
| T118A+G130A | 1 | |||||||
| P120S | 1 | |||||||
| T123I | 1 | |||||||
| T126N+D144E | 1 | |||||||
| G130S | 1 | |||||||
| T131N | 1 | |||||||
| M133S/T | 3 | |||||||
* Amino acid (aa) substitutions with immune-escape phenotype known from literature data, as well as respective numbers are shown in bold; other substitutions in the same aa positions and respective numbers are shown in plain text; aa substitutions within “a” determinant (aa positions 124–147) and respective numbers are shown in italics. ** Combined data are given on aa substitutions both with the known immune-escape phenotype and other substitutions in the same aa positions. n.d. – not detected. ▪ p < 0.05 (Fisher’s exact test) in pair-wise comparison between two time points. ▪▪ p < 0.05 (Fisher’s exact test) in pair-wise comparison between two HBV genotypes.